CN111284917B - Driver for aerosol drug delivery and aerosol drug delivery system containing the same - Google Patents
Driver for aerosol drug delivery and aerosol drug delivery system containing the same Download PDFInfo
- Publication number
- CN111284917B CN111284917B CN201811495974.6A CN201811495974A CN111284917B CN 111284917 B CN111284917 B CN 111284917B CN 201811495974 A CN201811495974 A CN 201811495974A CN 111284917 B CN111284917 B CN 111284917B
- Authority
- CN
- China
- Prior art keywords
- aerosol
- delivery system
- aerosol delivery
- drug
- acting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 257
- 238000012377 drug delivery Methods 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 66
- 229940079593 drug Drugs 0.000 claims abstract description 52
- 238000002156 mixing Methods 0.000 claims abstract description 43
- 238000005507 spraying Methods 0.000 claims abstract description 11
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 36
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 36
- 229940044601 receptor agonist Drugs 0.000 claims description 36
- 239000000018 receptor agonist Substances 0.000 claims description 36
- 239000007921 spray Substances 0.000 claims description 36
- 239000003862 glucocorticoid Substances 0.000 claims description 13
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 12
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 12
- 229960004436 budesonide Drugs 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 229960004017 salmeterol Drugs 0.000 claims description 12
- 230000007704 transition Effects 0.000 claims description 11
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 9
- 229960000289 fluticasone propionate Drugs 0.000 claims description 7
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 7
- 229960002848 formoterol Drugs 0.000 claims description 7
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 7
- 229960002714 fluticasone Drugs 0.000 claims description 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 5
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 5
- 229950008204 levosalbutamol Drugs 0.000 claims description 5
- 229960002052 salbutamol Drugs 0.000 claims description 5
- 235000011293 Brassica napus Nutrition 0.000 claims description 4
- 240000008100 Brassica rapa Species 0.000 claims description 4
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 claims description 4
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 4
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims description 4
- 229940015042 glycopyrrolate Drugs 0.000 claims description 4
- 229960001361 ipratropium bromide Drugs 0.000 claims description 4
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical group O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 4
- 229960000257 tiotropium bromide Drugs 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- FNXLCIKXHOPCKH-UHFFFAOYSA-N bromamine Chemical compound BrN FNXLCIKXHOPCKH-UHFFFAOYSA-N 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 238000000034 method Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000003754 machining Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
- B65D83/16—Actuating means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
- B65D83/60—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant with contents and propellant separated
- B65D83/66—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant with contents and propellant separated initially separated and subsequently mixed, e.g. in a dispensing head
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a driver for aerosol administration and an aerosol administration system containing the same. The driver comprises more than two vertically arranged drug delivery pipes, wherein each drug delivery pipe encloses to form a drug delivery channel, the driver further comprises a converging part and a vertically arranged drug mixing pipe, the drug mixing pipes enclose to form a drug mixing channel, the converging part and each drug delivery pipe are positioned on the same side of an inlet of the drug mixing channel, each platform part is communicated with the converging part, the converging part is communicated with the drug mixing channel, spraying holes are further formed in the side wall of the drug mixing channel, the diameter of each spraying hole is 0.25-0.6 mm, the depth of each spraying hole is 0.4-1.0 mm, and the distance between the center of each spraying hole and the top of the drug mixing pipe is 3.0-7.0 mm. The driver and the aerosol administration system can realize the delivery of more than two medicaments and can lead the medicaments to achieve ideal dispersing effect.
Description
Technical Field
The invention relates to an aerosol administration driver and an aerosol administration system comprising the same.
Background
The aerosol refers to a preparation which contains medicine, emulsion or suspension and proper propellant and is packaged in a pressure-resistant container with a special valve system, and when in use, the content is sprayed out in a mist form by the pressure of the propellant for pulmonary inhalation or directly spraying to mucous membranes of cavities, skin and space for disinfection. The aerosol can, valve and valve stem together comprise an aerosol delivery system. A common application of metered dose inhalation aerosols is to fill an aerosol canister in an actuator and then to effect drug delivery by depressing the canister.
However, in many cases, aerosols containing more than two APIs are required, and one method is to prepare compound aerosols, i.e. two or more APIs are put into one can to be administered, and this method has certain requirements on research and stability of the drug, and the other method is to administer two or more aerosols containing a single API simultaneously.
At present, in the prior art, only a driver suitable for one aerosol can body is not provided with drivers suitable for two or more aerosol can bodies, and further simultaneous administration of a plurality of products cannot be realized.
Disclosure of Invention
The invention aims to solve the technical problem that a driver suitable for two or more aerosol cans is not available in the prior art, and further the defect that simultaneous administration of a plurality of products cannot be realized is overcome, and provides a novel driver for aerosol administration and an aerosol administration system containing the driver. The driver for aerosol administration can insert more than two aerosol delivery systems therein, so as to realize the delivery of more than two medicaments and ensure that the medicaments achieve ideal dispersing effect. The aerosol administration system can realize the delivery of more than two kinds of medicines and can lead the medicines to achieve ideal dispersing effect.
The invention solves the technical problems by the following technical proposal:
The invention provides a driver for aerosol administration, which comprises more than two vertically arranged drug delivery pipes, a junction part and a vertically arranged drug mixing pipe, wherein each drug delivery pipe is surrounded to form a drug mixing channel, each drug delivery channel is sequentially divided into an interface part and a platform part along the drug delivery direction, each interface part is used for being matched with a valve rod of a corresponding aerosol delivery system, each platform part is used for enabling the valve rod of the aerosol delivery system to spray a drug along the drug delivery direction and limiting the valve rod of the aerosol delivery system to move along the drug delivery direction when the valve rod of the aerosol delivery system is pressed, the driver further comprises a junction part and a vertically arranged drug mixing pipe, the drug mixing pipe is surrounded to form a drug mixing channel, each junction part and each drug delivery pipe are positioned on the same side of an inlet of the drug mixing channel, each platform part is communicated with the junction part, a spray hole is further formed in the side wall of the drug mixing channel, the spray hole is used for spraying the drug, the spray hole is in the depth of the spray hole is between 0.0 mm and 0.25 mm, and 0.0 mm, and the spray hole is used for spraying the spray hole is in the depth of the spray hole is between 0.0.0 mm and 0mm and 0.0 mm.
In the above-described driver, the number of the drug delivery tubes is preferably 2.
In the above driver, preferably, each of the drug delivery tubes is disposed in the same manner, and each of the platform portions is located at the same height in the drug delivery tube.
In the above-mentioned driver, preferably, the interface portion is a cylindrical channel that is vertically disposed. More preferably, the distance between the axes of two adjacent interface portions is 18-22 mm, and even more preferably, the distance between the axes of two adjacent interface portions is 18-20 mm.
In the above-described actuator, the inner diameter of the interface portion is preferably equal to the outer diameter of the valve stem of the aerosol delivery system, typically with a machining tolerance of 1% -5%.
In the above-described actuator, preferably, the platform portion is a vertically arranged cylindrical passage.
In the above actuator, preferably, the inner diameter of the platform portion is ±0.6 mm of the inner diameter of the valve stem of the aerosol delivery system.
In the above-described actuator, preferably, the platform portion is in communication with the junction portion via a transition portion, and the transition portion is a circular arc tube segment capable of smoothly transitioning the platform portion and the junction portion. More preferably, the inner diameter of the transition portion is equal to the inner diameter of the interface portion.
In the above-mentioned driver, the inner diameter of the drug mixing tube is preferably 2.5 to 3.3 mm, more preferably 2.8 to 3.2 mm.
In the above driver, preferably, the outer diameter of the drug mixing tube is 3.5 mm.
In the above driver, preferably, the medicine mixing channel is a vertically arranged cylindrical channel.
In the above-described driver, the depth of the spray hole refers to the depth of the spray hole in a direction perpendicular to the medicine mixing tube. The diameter of the spray orifice is preferably 0.25-0.55 mm. The depth of the spray orifice is preferably 0.45-1.0 mm. The distance between the centre of the spray orifice and the top of the drug mixing tube is preferably 3.5-6.0 mm.
The number of spray holes is preferably 1.
In the above driver, preferably, the driver is made of plastic, more preferably PET material, PBT material, PE material or PP material. The actuator may be manufactured, for example, by one-time molding by die machining.
In the above-mentioned actuator, the height of the actuator is preferably 40-80 mm.
In the above driver, the driver further has a housing, and the housing can fix the drug delivery tube and does not affect the spray hole to spray the drug.
The invention also provides an aerosol administration system which comprises the driver for aerosol administration and more than two aerosol delivery systems, wherein a valve rod of each aerosol delivery system is matched with one interface part, and the inner aperture of the valve rod of the aerosol delivery system is 2.5-3.3 mm.
In the aerosol administration system, the aerosol delivery system generally comprises a valve rod, a valve and a tank body containing aerosol, wherein the valve of the aerosol delivery system and the tank body of the aerosol delivery system are sealed through a sealing device after medicine is filled, and sealing is realized through a rubber gasket.
In the aerosol delivery system described above, the valve stem of the aerosol delivery system preferably has an internal bore diameter of 2.8 to 3.2 mm, for example 3.16 mm.
In the above aerosol delivery system, preferably, the valve stem of the aerosol delivery system has an outer diameter of 3.5 mm.
In the above aerosol delivery system, preferably, the distance between the axes of the valve stems of adjacent two of said aerosol delivery systems is 18-22 mm.
In the above aerosol delivery system, preferably, the valve of the aerosol delivery system has an outer diameter of 14-16 mm.
In the aerosol administration system, preferably, a valve of the aerosol delivery system contains a spring assembly, the spring assembly is used for returning a tank body of the aerosol delivery system to an equilibrium position after being pressed, and the expansion and contraction amount of the spring assembly is 0.6-1.2 mm.
In the above aerosol delivery system, preferably, the aerosol delivery system has a canister outer diameter of 14-16 mm.
In the aerosol delivery system, preferably, the bottom of the canister of each of the aerosol delivery systems is at the same height.
In the above aerosol administration system, preferably, the aerosol administration system is further provided with a cap provided with a groove matched with the bottom of the can body of the aerosol delivery system, and the cap can simultaneously move the can body of the aerosol delivery system downwards along the vertical direction. In the technical scheme, the tank body can be fixed through the design of the groove, and in the pressing process, two tank bodies can be ensured to be pressed simultaneously.
In the above aerosol administration system, preferably, the aerosol in the canister of at least one of the aerosol delivery systems is a beta receptor agonist and the aerosol in the canister of at least one of the aerosol delivery systems is an inhaled glucocorticoid, or the aerosol in the canister of at least one of the aerosol delivery systems is a beta receptor agonist and the aerosol in the canister of at least one of the aerosol delivery systems is an anticholinergic inhibitor, more preferably, the aerosol in the canister of at least one of the aerosol delivery systems is a beta receptor agonist, and the aerosol in the canister of at least one of the aerosol delivery systems is an inhaled glucocorticoid and the aerosol in the canister of at least one of the aerosol delivery systems is an anticholinergic inhibitor.
Wherein the beta receptor agonist can be a long-acting beta receptor agonist or a short-acting beta receptor agonist, the long-acting beta receptor agonist is a beta receptor agonist with the action maintenance time of 11-12 hours, and the short-acting beta receptor agonist is a beta receptor agonist with the action maintenance time of 4-6 hours, preferably salmeterol aerosol, formoterol aerosol, vilanaterol aerosol, salbutamol aerosol or levosalbutamol aerosol, more preferably a short-acting salbutamol sulfate aerosol or a long-acting salmeterol aerosol.
Wherein, the inhaled glucocorticoid is preferably fluticasone aerosol or budesonide aerosol, more preferably fluticasone propionate aerosol.
Wherein the anticholinergic inhibitor is preferably ipratropium bromide aerosol, tiotropium bromide aerosol or glycopyrrolate aerosol.
In a preferred embodiment of the above aerosol delivery system, the combination of the beta receptor agonist and the inhaled glucocorticoid is such that the combination of a long acting salmeterol aerosol with a fluticasone aerosol, or a long acting formoterol aerosol with a budesonide aerosol, or a long acting vilanaterol aerosol with a fluticasone aerosol.
In a preferred embodiment of the above aerosol delivery system, the combination of the beta receptor agonist and the inhaled glucocorticoid is in the form of a combination of a short acting salbutamol sulphate aerosol with budesonide aerosol or a combination of a long acting salmeterol aerosol with fluticasone propionate aerosol.
In a preferred embodiment of the above aerosol delivery system, the combination of the beta receptor agonist and the anticholinergic inhibitor is a combination of a short-acting salbutamol aerosol with ipratropium bromide aerosol, or a combination of a short-acting levosalbutamol aerosol with tiotropium bromide aerosol, or a combination of a long-acting formoterol aerosol with glycopyrrolate aerosol, or a combination of a long-acting vilantro aerosol with a turnip bromide aerosol.
In a preferred embodiment of the above aerosol delivery system, the combination of the beta receptor agonist, the inhaled glucocorticoid and the anticholinergic inhibitor is a combination of a long-acting veland aerosol, a turnip bromoamine aerosol and a budesonide aerosol.
In the above preferred embodiments, the definition of the long-acting salmeterol aerosol, the long-acting formoterol aerosol and the long-acting valterol aerosol are the same as the definition of the long-acting beta receptor agonist, and the definition of the short-acting salbutamol aerosol, the short-acting levosalbutamol aerosol and the short-acting salbutamol sulfate aerosol are the same as the definition of the short-acting beta receptor agonist.
The invention has the positive progress effects that the driver for aerosol administration can insert more than two aerosol delivery systems into the driver, thereby realizing the delivery of more than two medicaments and enabling the medicaments to achieve ideal dispersing effect. The aerosol administration system can realize the delivery of more than two kinds of medicines and can lead the medicines to achieve ideal dispersing effect.
Drawings
FIG. 1 is a cross-sectional view of the vertical plane of the axis of the drug delivery channel and the axis of the drug mixing channel of the driver of embodiments 1-5 of the present invention;
FIG. 2 is a cross-sectional view of the actuator of embodiments 1-5 of the present invention in a vertical plane along which the axis of the spray orifice lies;
fig. 3 is a cross-sectional view of the drug delivery system of embodiments 1-5 of the present invention taken along a vertical plane of the axis of the drug delivery channel of the driver and the axis of the drug mixing channel.
Reference numerals illustrate:
drug delivery tube 10
Interface 11
Platform 12
Transition portion 20
Drug mixing tube 30
Drug mixing channel 31
Spray orifice 32
Depth h of spray hole
Aerosol delivery system 40
Junction 50
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
In the examples described below, salbutamol sulphate aerosol (200 presses per bottle, 100 μg salbutamol sulphate per press), budesonide aerosol (100 presses per bottle, 200 μg budesonide per press) were commercially available from offshore pharmaceutical signal friendship pharmaceutical company, ltd, and fluticasone propionate aerosol and salmeterol aerosol were commercially available from glauceine smith pharmaceutical company.
In the examples below, long acting beta receptor agonists refer to beta receptor agonists with a duration of action of 11-12 hours, and short acting beta receptor agonists refer to beta receptor agonists with a duration of action of 4-6 hours.
Examples 1 to 5
(1) Actuator for aerosol administration
The driver for aerosol administration shown in fig. 1 and 2 comprises more than two vertically arranged drug delivery pipes 10, wherein each drug delivery pipe 10 surrounds to form a drug delivery channel, each drug delivery channel is sequentially divided into an interface part 11 and a platform part 12 along the drug delivery direction, each interface part 11 is used for being matched with a valve rod of a corresponding aerosol delivery system, each platform part 12 is used for enabling the valve rod of the aerosol delivery system to spray out drugs along the drug delivery direction and limiting the valve rod of the aerosol delivery system to move along the drug delivery direction when the valve rod of the aerosol delivery system is pressed, the driver further comprises a junction part 50 and a vertically arranged drug mixing pipe 30, the drug mixing pipe 30 surrounds to form a drug mixing channel 31, the junction part 50 and each drug delivery pipe 10 are positioned on the same side of an inlet of the drug mixing channel 31, each platform part 12 is communicated with the junction part 50, a spray hole 32 is further arranged on the side wall of the drug mixing channel 31, and the spray hole 32 is used for spraying out drugs.
Wherein the number of drug delivery tubes 10 is 2.
Wherein each of the drug delivery tubes 10 is arranged in the same manner, and each of the platform portions 12 is located at the same height in the drug delivery tube 10.
Wherein the interface part 11 is a vertically arranged cylindrical channel.
Where the inner diameter of the interface portion 11 is equal to the outer diameter of the valve stem of the aerosol delivery system, there will typically be a machining tolerance of 1% -5%.
Wherein the platform portion 12 is a vertically disposed cylindrical channel.
Wherein the inner diameter of the platform portion 12 is + -0.6 mm of the inner diameter of the valve stem of the aerosol delivery system.
Wherein the platform part and the junction part 50 are communicated through a transition part, the transition part 20 is a circular arc pipe section capable of enabling the platform part 12 and the junction part 50 to be in smooth transition, and the inner diameter of the transition part 20 is equal to the inner diameter of the interface part 11.
Wherein the outer diameter of the drug mixing tube 30 is 3.5 mm.
Wherein the medicine mixing passage 31 is a vertically arranged cylindrical passage.
The depth h of the spray holes refers to the depth of the spray holes 32 in the direction perpendicular to the drug mixing tube 30 (as shown in fig. 2), and the number of the spray holes 32 is 1.
The driver is made of plastic, such as PET material, PBT material, PE material or PP material.
Wherein the driver further has a housing capable of holding the drug delivery tube 10 without affecting the ejection of the drug from the spray aperture 32.
(2) Aerosol delivery system
An aerosol delivery system as shown in fig. 3, the aerosol delivery system comprising the actuator as shown in fig. 1 and 2 and two or more aerosol delivery systems 40 for aerosol delivery as described above, the valve stem of each aerosol delivery system 40 being associated with an interface portion 11.
The aerosol delivery system 40 generally comprises a valve stem, a valve and a can containing aerosol, wherein the valve of the aerosol delivery system 40 and the can of the aerosol delivery system 40 are sealed by a sealing device after filling the medicament, and the sealing is realized by a rubber gasket.
Wherein the valve stem of the aerosol delivery system 40 has an outer diameter of 3.5 millimeters.
Wherein the valve of the aerosol delivery system 40 has an outer diameter of 14-16 millimeters.
Wherein the valve of the aerosol delivery system 40 contains a spring assembly for returning the canister of the aerosol delivery system 40 to the equilibrium position after pressing, the spring assembly having a spring extension of 0.6-1.2 mm.
Wherein the canister outer diameter of the aerosol delivery system 40 is 14-16 millimeters.
Wherein the bottom of the canister of each aerosol delivery system 40 is at the same height.
Wherein the aerosol delivery system is further provided with a cap provided with a recess cooperating with the bottom of the canister of the aerosol delivery system 40, the cap being capable of simultaneously moving the canister of the aerosol delivery system 40 downwards in a vertical direction. In the technical scheme, the tank body can be fixed through the design of the groove, and in the pressing process, two tank bodies can be ensured to be pressed simultaneously.
Wherein, the relevant structural parameters of the actuator for aerosol administration and the aerosol administration system are shown in the following table.
The types and combinations of aerosols in the aerosol delivery system 40 of examples 1-5 correspond to those of the relevant tables of effect examples 1-5, respectively.
Effect examples 1-2 combinations of short-acting salbutamol sulphate aerosols and budesonide aerosols
Wherein, the specification of salbutamol sulfate aerosol is 100 micrograms/press, and budesonide aerosol is 200 micrograms/press and 100 micrograms/press. The results of HPLC content measurements for drug delivery systems containing the following combinations of aerosol delivery systems 40 are shown in the following table:
Effect examples 3-5 combinations of fluticasone propionate aerosols and long-acting salmeterol aerosols
Wherein, the specification of the fluticasone propionate aerosol is 50 microgram/press, 125 microgram/press and 250 microgram/press, and the specification of the salmeterol aerosol is 25 microgram/press. The results of HPLC content measurements for drug delivery systems containing the following combinations of aerosol delivery systems 40 are shown in the following table:
While specific embodiments of the invention have been described above, it will be appreciated by those skilled in the art that this is by way of example only, and the scope of the invention is defined by the appended claims. Various changes and modifications to these embodiments may be made by those skilled in the art without departing from the principles and spirit of the invention, but such changes and modifications fall within the scope of the invention.
Claims (18)
1. A driver for aerosol administration is characterized by comprising more than two vertically arranged drug delivery pipes, a converging part and a vertically arranged drug mixing pipe, wherein each drug delivery pipe is surrounded to form a drug mixing channel, the interior of each drug delivery channel is sequentially divided into an interface part and a platform part along the drug delivery direction, each interface part is used for being matched with a valve rod of a corresponding aerosol delivery system, each platform part is used for enabling the valve rod of the aerosol delivery system to spray a drug along the drug delivery direction and limiting the valve rod of the aerosol delivery system to move along the drug delivery direction when the valve rod of the aerosol delivery system is pressed, the driver also comprises a converging part and a vertically arranged drug mixing pipe, the drug mixing pipe is surrounded to form a drug mixing channel, the converging part and each drug delivery pipe are positioned on the same side of an inlet of the drug mixing channel, each platform part is communicated with the converging part, a spray hole is further formed in the side wall of the drug mixing channel, the spray hole is used for spraying the drug with a depth of between 0.0 mm and 0.7 mm, and 0mm from the spray hole is used for spraying the spray hole to the top of the spray hole;
the platform part is communicated with the junction part through a transition part, and the transition part is an arc pipe section capable of enabling the platform part and the junction part to be in smooth transition;
the interface part is a cylindrical channel which is vertically arranged, and the distance between the axes of two adjacent interface parts is 18-22 mm;
The inner diameter of the drug mixing tube is 2.5-3.3 mm;
The height of the driver is 40-80 mm;
The valve stem of the aerosol delivery system has an internal bore diameter of 2.5-3.3 mm.
2. The actuator for aerosol administration of claim 1, wherein the number of said drug delivery tubes is 2;
and/or, the arrangement mode of each drug delivery tube is the same, and each platform part is positioned at the same height in the drug delivery tube.
3. The aerosol delivery actuator of claim 1, wherein the distance between the axes of adjacent two of said interface portions is 18-20 mm;
And/or an inner diameter of the interface portion is equal to an outer diameter of a valve stem of the aerosol delivery system;
And/or the platform part is a vertically arranged cylindrical channel;
and/or the inner diameter of the platform portion is ± 0.6 millimeters of the inner diameter of the valve stem of the aerosol delivery system.
4. The aerosol delivery actuator of claim 1, wherein the drug mixing tube has an inner diameter of 2.8-3.2 millimeters;
And/or the outer diameter of the drug mixing tube is 3.5 millimeters;
And/or the medicine mixing channel is a vertically arranged cylindrical channel.
5. The aerosol delivery actuator of claim 1, wherein the spray orifice has a diameter of 0.25 to 0.55 millimeters;
and/or the depth of the spray hole is 0.45-1.0 mm;
And/or the distance between the center of the spray hole and the top of the medicine mixing tube is 3.5-6.0 mm;
and/or the number of the spraying holes is 1.
6. The actuator for aerosol administration of claim 1, wherein the actuator is plastic;
And/or the driver further has a housing capable of holding the drug delivery tube without affecting the spray orifice to eject the drug.
7. The actuator for aerosol administration of claim 6, wherein the actuator is made of PET material, PBT material, PE material or PP material.
8. An aerosol delivery system comprising the actuator for aerosol delivery of any of claims 1 to 7 and two or more aerosol delivery systems, each of the valve stems of the aerosol delivery systems being mated with one of the interface portions.
9. The aerosol delivery system of claim 8, wherein the valve stem of the aerosol delivery system has an internal bore diameter of 2.8-3.2 millimeters;
and/or the valve stem of the aerosol delivery system has an outer diameter of 3.5 millimeters;
And/or the distance between the axes of the valve stems of adjacent two of said aerosol delivery systems is 18-22 mm;
and/or the valve of the aerosol delivery system has an outer diameter of 14-16 mm;
And/or, the valve of the aerosol delivery system comprises a spring assembly, the spring assembly is used for restoring the tank body of the aerosol delivery system to the balance position after being pressed, and the expansion and contraction amount of the spring assembly is 0.6-1.2 mm;
And/or the outer diameter of the canister of the aerosol delivery system is 14-16 mm;
And/or the bottom of the canister of each of the aerosol delivery systems is at the same height;
and/or the aerosol administration system is further provided with a cap provided with a groove matched with the bottom of the tank body of the aerosol delivery system, and the cap can simultaneously move the tank body of the aerosol delivery system downwards along the vertical direction.
10. The aerosol delivery system of claim 8 or 9, wherein in the aerosol delivery system, the aerosol in the canister of at least one of the aerosol delivery systems is a beta receptor agonist and the aerosol in the canister of at least one of the aerosol delivery systems is an inhaled glucocorticoid, or wherein the aerosol in the canister of at least one of the aerosol delivery systems is a beta receptor agonist and the aerosol in the canister of at least one of the aerosol delivery systems is an anticholinergic inhibitor.
11. The aerosol delivery system of claim 10, wherein the aerosol in the canister of at least one of the aerosol delivery systems is a beta receptor agonist, the aerosol in the canister of at least one of the aerosol delivery systems is an inhaled glucocorticoid and the aerosol in the canister of at least one of the aerosol delivery systems is an anticholinergic inhibitor.
12. The aerosol delivery system of claim 10, wherein the beta receptor agonist is a long-acting beta receptor agonist or a short-acting beta receptor agonist, wherein the long-acting beta receptor agonist is a beta receptor agonist having a duration of action of 11 to 12 hours, and wherein the short-acting beta receptor agonist is a beta receptor agonist having a duration of action of 4 to 6 hours.
13. The aerosol delivery system of claim 12, wherein the beta receptor agonist is salmeterol aerosol, formoterol aerosol, vilarerol aerosol, salbutamol aerosol, or levalbuterol aerosol.
14. The aerosol delivery system of claim 12, wherein the beta receptor agonist is a short-acting salbutamol sulfate aerosol or a long-acting salmeterol aerosol.
15. The aerosol delivery system of claim 10, wherein the inhaled glucocorticoid is a fluticasone aerosol or a budesonide aerosol.
16. The aerosol delivery system of claim 15, wherein the inhaled glucocorticoid is a fluticasone propionate aerosol.
17. The aerosol delivery system of claim 10, wherein the anticholinergic inhibitor is ipratropium bromide aerosol, tiotropium bromide aerosol, or glycopyrrolate aerosol.
18. The aerosol delivery system of claim 10, wherein the combination of the beta receptor agonist and the inhaled glucocorticoid is such that the combination of a long-acting salmeterol aerosol with a fluticasone aerosol, or the combination of a long-acting formoterol aerosol with a budesonide aerosol, or the combination of a long-acting vilarole aerosol with a fluticasone aerosol, or the combination of the beta receptor agonist and the inhaled glucocorticoid is such that the combination of a short-acting salbutamol sulfate aerosol with a budesonide aerosol, or the combination of a long-acting salmeterol aerosol with a fluticasone propionate aerosol;
Or the combination of the beta receptor agonist and the anticholinergic inhibitor is as follows, namely, the combination of short-acting salbutamol aerosol and ipratropium bromide aerosol, or the combination of short-acting levosalbutamol aerosol and tiotropium bromide aerosol, or the combination of long-acting formoterol aerosol and glycopyrrolate aerosol, or the combination of long-acting vilantro aerosol and turnip bromide aerosol;
Or the combination of the beta receptor agonist, the inhaled glucocorticoid and the anticholinergic inhibitor is a combination of a long-acting viland aerosol, a turnip bromoamine aerosol and a budesonide aerosol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811495974.6A CN111284917B (en) | 2018-12-07 | 2018-12-07 | Driver for aerosol drug delivery and aerosol drug delivery system containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811495974.6A CN111284917B (en) | 2018-12-07 | 2018-12-07 | Driver for aerosol drug delivery and aerosol drug delivery system containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111284917A CN111284917A (en) | 2020-06-16 |
| CN111284917B true CN111284917B (en) | 2024-12-10 |
Family
ID=71018924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811495974.6A Active CN111284917B (en) | 2018-12-07 | 2018-12-07 | Driver for aerosol drug delivery and aerosol drug delivery system containing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111284917B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119792738B (en) * | 2025-02-12 | 2025-10-28 | 黔东南苗族侗族自治州民族医药研究院(黔东南苗族侗族自治州苗医苗药研究院) | Dual-channel drug feeder for respiratory department |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013079082A (en) * | 2011-09-30 | 2013-05-02 | Daizo:Kk | Apparatus for mixing and ejecting two liquids, and ejection product using the same |
| CN209427409U (en) * | 2018-12-07 | 2019-09-24 | 上海上药信谊药厂有限公司 | The driver of aerosol drug delivery and aerosol delivery systems containing it |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4116387A (en) * | 1976-05-11 | 1978-09-26 | Eastfield Corporation | Mist generator |
| PT689874E (en) * | 1994-06-28 | 2002-03-28 | Aventis Behring Gmbh | DEVICE FOR SPRAYING A MIXTURE OF TWO COMPONENTS |
| US7906473B2 (en) * | 2002-09-13 | 2011-03-15 | Bissell Homecare, Inc. | Manual spray cleaner |
| DE102006014433A1 (en) * | 2006-03-27 | 2007-10-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Metered aerosols for the administration of pharmaceutical preparations |
| US9303820B2 (en) * | 2008-10-14 | 2016-04-05 | Harris Richard Miller | Chemiluminescent aerosol spray |
| NZ628562A (en) * | 2012-03-09 | 2015-08-28 | Vectura Gmbh | Mixing channel for an inhalation device and inhalation device |
| US9050432B2 (en) * | 2013-04-03 | 2015-06-09 | Sheng-I Lu | Medical apparatus for atomizing water, gas, and liquid medication |
| CN105413906A (en) * | 2015-12-30 | 2016-03-23 | 中山市美捷时包装制品有限公司 | Mixed aerosol device |
| CN106943350A (en) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | Aerosol and preparation method containing muscarinic receptor antagonist and β 2 receptor agonist |
-
2018
- 2018-12-07 CN CN201811495974.6A patent/CN111284917B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013079082A (en) * | 2011-09-30 | 2013-05-02 | Daizo:Kk | Apparatus for mixing and ejecting two liquids, and ejection product using the same |
| CN209427409U (en) * | 2018-12-07 | 2019-09-24 | 上海上药信谊药厂有限公司 | The driver of aerosol drug delivery and aerosol delivery systems containing it |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111284917A (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103282070B (en) | nasal spray device | |
| RU2561833C2 (en) | Dosing inhaler and method of thereof application | |
| US12357568B2 (en) | Aerosol formulation for COPD | |
| CN104755122B (en) | Quantitative dispensing valve | |
| US20050241634A1 (en) | Two-chamber cartridge for propellant-free metering aerosols | |
| US7793806B2 (en) | Metering valve | |
| CN101784299A (en) | Metered dose inhaler actuator | |
| CN1874756B (en) | Pharmaceutical metered dose inhaler and related methods | |
| CN111284917B (en) | Driver for aerosol drug delivery and aerosol drug delivery system containing the same | |
| KR20080093971A (en) | One-way valve assembly with continuous sealing and fluid delivery system preparation for use therein | |
| JP2009502285A (en) | Nasal inhaler nozzle | |
| EP3139985B1 (en) | Aerosol device | |
| CN209427409U (en) | The driver of aerosol drug delivery and aerosol delivery systems containing it | |
| US10968033B2 (en) | Metering valve and fluid product dispensing device comprising such a valve | |
| CN223208813U (en) | Breathe internal medicine ware of spouting | |
| CN202213866U (en) | Spray bottle for small-volume spraying device and small-volume spraying device using same | |
| WO2010133817A1 (en) | Valve assemblies, dispensing containers and kits therefore | |
| CN102805891A (en) | Spray bottle for small-capacity spray device | |
| GB2450327A (en) | Inhaler with air flow control | |
| CN103099735A (en) | Inner liner type medicine bottle for ketorolac tromethamine spray | |
| EP1430865A2 (en) | Dispenser device | |
| CN120897772A (en) | Improvements relating to the plugging of containers | |
| GB2402667A (en) | Dispensing device | |
| HK1229739A1 (en) | Nasal spray device | |
| HK1186994B (en) | Nasal spray device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |